TDO2 and melanoma: The failure of IDO1 inhibitors for melanoma therapy might be related to an enhanced TDO activity or an elevated expression of IL-4-induced gene 1, another tryptophan-metabolizing enzyme that induces immunosuppression by producing AHR ligands (147, 148).